• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 3. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Cinchona alkaloids Cinchona alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Cinchona alkaloids

Research Briefing on Cinchonine Tosylate (189309-24-8): Recent Advances and Applications in Chemical Biology and Medicine

Cinchonine Tosylate (CAS: 189309-24-8) is a derivative of cinchona alkaloids, which have long been recognized for their pharmacological properties. Recent studies have highlighted its potential in various therapeutic applications, including antimalarial, anticancer, and antiviral activities. This research briefing aims to synthesize the latest findings on Cinchonine Tosylate, focusing on its chemical properties, mechanisms of action, and emerging applications in drug development.

One of the most significant advancements in the study of Cinchonine Tosylate is its role as a chiral auxiliary in asymmetric synthesis. Researchers have demonstrated its efficacy in facilitating enantioselective reactions, which are critical for the production of optically active pharmaceuticals. A 2023 study published in the Journal of Medicinal Chemistry reported that Cinchonine Tosylate could significantly improve the yield and enantiomeric excess (ee) of certain chiral intermediates, making it a valuable tool in synthetic chemistry.

In the realm of anticancer research, Cinchonine Tosylate has shown promise as a modulator of cellular pathways involved in apoptosis and autophagy. A recent preclinical study revealed that this compound could inhibit the proliferation of cancer cells by targeting the PI3K/AKT/mTOR signaling pathway. These findings, published in Cancer Research, suggest that Cinchonine Tosylate may serve as a lead compound for the development of novel anticancer agents, particularly for tumors resistant to conventional therapies.

Another area of interest is the potential antiviral activity of Cinchonine Tosylate. Preliminary studies have indicated that it may interfere with the replication cycles of certain RNA viruses, including SARS-CoV-2. While these results are still in the early stages, they open new avenues for research into broad-spectrum antiviral drugs. Researchers are currently exploring the structural modifications of Cinchonine Tosylate to enhance its antiviral efficacy and reduce potential side effects.

Despite these promising developments, challenges remain in the clinical translation of Cinchonine Tosylate. Issues such as bioavailability, toxicity, and formulation stability need to be addressed through further research. Recent efforts have focused on nanotechnology-based delivery systems to improve the pharmacokinetic profile of Cinchonine Tosylate. A 2024 study in Advanced Drug Delivery Reviews highlighted the use of liposomal encapsulation to enhance its solubility and targeted delivery.

In conclusion, Cinchonine Tosylate (189309-24-8) represents a versatile compound with significant potential in chemical biology and medicine. Its applications span from asymmetric synthesis to therapeutic interventions, underscoring its importance in modern drug discovery. Future research should prioritize overcoming the existing limitations and exploring its full therapeutic potential. This briefing underscores the need for interdisciplinary collaboration to accelerate the development of Cinchonine Tosylate-based therapies.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)